Anupam Rasayan enters pharma space with Bliss GVS deal; stock slips 4% from day’s high

Shares of Anupam Rasayan India  witnessed volatile trading on Monday after the chemical manufacturer announced the acquisition of a significant stake in Bliss GVS Pharma to strengthen its presence across the pharmaceutical value chain. The move will help the Gujarat-based company foray into finished dosage formulations and integrated life sciences manufacturing.

Ending a two-session losing streak, Anupam Rasayan shares opened 2.4% higher at ₹1,396.85 on the BSE. However, the stock pared early gains and slipped as much as 3.86% from the day’s high to touch an intraday low of ₹1,342.85. The company’s market capitalisation stood at around ₹15,380 crore at the time of reporting.

The stock had touched a 52-week high of ₹1,415.40 on May 7, 2026, while its 52-week low stood at ₹934 on May 23, 2025. The counter has delivered a positive return of nearly 2% so far in calendar year 2026 and has rallied over 36% in the past 12 months. The stock is up more than 1% over the last one month.

Enters formulations business with acquisition

The sharp movement in the stock came after Anupam Rasayan announced that it has entered into a definitive agreement to acquire a 43.3%-48.2% equity stake in Bliss GVS Pharma, along with an open offer to the public shareholders of the company.

The acquisition will be financed through a combination of a ₹300 crore term loan and non-controlling non-voting equity instruments for the remaining amount, the company said in an exchange filing on May 23.

Bliss GVS Pharma is engaged in the development, manufacturing, marketing, and export of pharmaceutical dosage forms including suppositories, pessaries, tablets, capsules, syrups, injectables, creams, and ointments. The company has a strong international presence across Africa, Asia, and Latin America and is known for its niche leadership in suppositories and pessaries.

Commenting on the acquisition, Anand Desai, Managing Director of Anupam Rasayan India, said the deal marks another important milestone in the company’s vision of building an integrated global life sciences and specialty pharmaceutical platform.

“This will strategically strengthen our presence across the pharmaceutical value chain, spanning KSMs to finished dosage formulations. Bliss GVS Pharma brings well-established capabilities in niche dosage forms, a strong international footprint, differentiated brands, and expertise across multiple therapeutic segments,” he said.

According to the company, the acquisition will boost its presence across the pharmaceutical value chain, spanning key starting materials (KSMs) to finished dosage formulations. The company expects the transaction to create synergies through broader product offerings, stronger regulated market presence, improved customer engagement, and accelerated innovation across regulated and semi-regulated markets.

The company also believes the acquisition will deepen backward integration capabilities and expand its global footprint, particularly in Europe and the Americas, supported further by its earlier Jayhawk acquisition.

(DISCLAIMER: The views and opinions expressed by investment experts on fortuneindia.com are either their own or of their organisations, but not necessarily that of fortuneindia.com and its editorial team. Readers are advised to consult certified experts before taking investment decisions.)